ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | 13.9% YoY; CDMO segment up 18.6%. |
|---|---|
| Margins | EBITDA margins improved 238 bps YoY to 15%. |
| Order book | USD 25M Zambia order on track for H2 recognition. |
| Demand visibility | Strong CDMO demand; healthy visibility for Q2. |
| Management confidence | High for double-digit volume growth in coming quarters. |
Growth
Revenue rose 13.9% YoY to INR 1,167 Cr; EBITDA grew 35.4% YoY; PAT up 56.1% YoY to INR 101 Cr.
Outlook
Guided for 14-15% EBITDA margins; new Baddi facility live by fiscal end; Zambia revenue recognition in H2FY27.
Risks
API price volatility, muted international branded formulations performance, and temporary margin impact from expanded field force in domestic segments.
Last quarter's promises, checked
Delivered
- Guided double-digit CDMO volume growth → delivered 18.6% CDMO revenue growth (= BEAT)
- Guided 29% effective tax rate → delivered 29% (= BEAT)
- Guided FY26 capex of ~INR 222 Cr → delivered INR 222 Cr (= BEAT)
Partly delivered
- Guided 13-14% CDMO margins → delivered 15% (= BEAT)
- Guided Zambia supplies to start Q2FY27 → delayed to H2FY27 (= PARTIAL)
Missed
- Guided domestic branded growth above IPM rates → delivered 7.3% vs 8-9% IPM (= MISS)
Earnings Call Transcript filed with BSE, NSE: AKUMS. Summary written with AI assistance from the document.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹768.80
- Market cap
- ₹12,100 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 33.3×Sector 43.8×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Consolidated revenue ₹1,342 Cr (+31.9% YoY) and EBITDA ₹195 Cr (+106%), led by CDMO volumes. Management gave no numeric guidance. API still loss-making and domestic branded growth is only about 8%.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has fully utilized its IPO proceeds totaling Rs. 680 Crore as of September 30, 2026. Consequently, further monitoring agency reports are no longer required.
- Value
- ₹680.0 Cr
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27: revenue INR 1,342 cr (+31.9% YoY), EBITDA INR 195 cr (14.5% margin), PAT INR 115 cr (+168.3% YoY). CDMO-led growth; API losses narrowing.
Akums Drugs & Pharmaceuticals Results Update
Akums reported Q2 FY27 revenue of ₹1,342 crore, up 31.9%, and PAT of ₹115 crore, up 168%. The release is a press update with highlights, not the full results statement.
Akums Drugs & Pharmaceuticals Q2 FY27 Results: Net Profit ₹114.6 Cr, Up 168.4% YoY
Akums Drugs & Pharmaceuticals Ltd reported revenue from operations of ₹1,342 Cr (+31.9% YoY) and net profit of ₹114.6 Cr (+168.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹114.6 Cr · +168.4% YoY
Akums Drugs & Pharmaceuticals Management Change
Akums Drugs announced the resignation of Mr. Sunil Jaiswal, SVP R&D and Senior Management Personnel, effective 31 October 2026. The resignation was submitted on 5 August 2026 citing family commitments.